Skip to the page

Data / Drug companies / TerSera Therapeutics LLC

TerSera Therapeutics LLC: 9 products in the FDA NDC directory, labeler code 70720

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

TerSera Therapeutics LLC (labeler code 70720) lists 9 products in the FDA National Drug Code Directory, covering 6 finished drugs by generic name. By type: 9 prescription drugs. Its main marketing category is new drug applications (NDA). The newest product started marketing on January 15, 2021.

The request: Watch TerSera Therapeutics LLC (FDA labeler code 70720): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
70720
Products in commercial distribution
9
Packages
9
Finished drugs by generic name
6
Prescription products
9
Over the counter products
0
Flagged as original packager
9 of 9 products that carry the flag
Started marketing in the last 12 months
0
Earliest marketing start
October 7, 2015
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
New drug applications (NDA)888.9%
Biologics (BLA)111.1%

Products by type

TypeProductsShare
Prescription drugs9100%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Injection, solution333.3%
Implant222.2%
Tablet222.2%
Injection, solution, concentrate111.1%
Injection111.1%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Margenza70720-022Injection, solution, concentrateBiologics (BLA)January 15, 2021
Xermelo70720-125TabletNew drug applications (NDA)October 5, 2020
Quzyttir70720-100InjectionNew drug applications (NDA)November 13, 2019
Prialt70720-723Injection, solutionNew drug applications (NDA)October 15, 2018
Prialt70720-722Injection, solutionNew drug applications (NDA)October 15, 2018
Prialt70720-720Injection, solutionNew drug applications (NDA)October 15, 2018
Zoladex70720-950ImplantNew drug applications (NDA)March 31, 2018
Zoladex70720-951ImplantNew drug applications (NDA)January 26, 2018
Varubi70720-101TabletNew drug applications (NDA)October 7, 2015

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.